IgM Concentrate
Trade name: trimodulin
Biologicalexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Oct 6, 2020 (NCT04576728)
Timeline
Indications
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05722938 | Phase 3 | Sep 9, 2023 | Biotest Pharmaceuticals, Gottfried Wilhelm Leibniz Universität Hannover |
| NCT05531149 | Phase 3 | Jan 10, 2023 | Biotest Pharmaceuticals, Gottfried Wilhelm Leibniz Universität Hannover |
| NCT04576728 | Phase 2 | Oct 6, 2020 | Biotest Pharmaceuticals, University of Barcelona |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biotest Pharmaceuticals | For profit | 3 | 3 | 2 | 2020 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 2 | 0 | 1 | 2023 |
| University of Barcelona | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1